



Ark Surgical Ltd. is a privately held Israeli medical device company dedicated to improving the provision of surgical care to the benefit of women worldwide.

LapBox™


Ark Surgical is answering the FDA's call to address a pressing clinical need affecting every third woman by the age 65 who will undergo hysterectomy surgery to remove the uterus. The Company is commercializing LapBox, a containment system that allows simple and safe encapsulation of the uterus in a double wall chamber enabling uterus removal by a minimally invasive laparoscopic procedure.



LapBox provides a fully contained space within the inflated abdomen, inside which the surgeon can effectively and safely morcellate large organs using power or manual morcellation, without the risks associated with tissue morcellation.

Clinical Need

Laparoscopic surgery is currently the standard of care for many surgical procedures as it is performed through a small incision in an outpatient procedure (no overnight stay), offers less pain, smaller scar, faster recuperation and fewer complications. Despite the clear benefits of laparoscopic surgery, it is currently used less frequently for GYN procedures due to the fear of spread of undiagnosed cancer throughout the body during surgery. This means that **each year 1,500,000 women worldwide** may undergo open surgery that is associated with high cost of care for the provider and payer, large painful 12cm incisions, long hospitalization, complications and even death.



Go-To-Market

Based on the enthusiastic feedback from leading surgeons in the US and Europe who have expressed interest in serving as initial centers of excellence upon market launch, LapBox is expected to be widely adopted in the market. To date, no device for this problem has gained broad market adoption due to their cumbersome mode of operation and safety concerns, leaving a significant unaddressed clinical need which LapBox will fill.

LapBox is expected to shorten hospitalization stays by 300%, save hundreds of millions of dollars to hospitals and insurers and save the lives of 4,500 women every year.

LapBox™



LapBox is currently in clinical use as part of a First in Human clinical study in Israel



LapBox is protected worldwide by 3 patent applications covering its unique concept and structure



Market launch in the US and EU is planned for the second half of 2021



Addresses a potential market of approximately \$500M annually